Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States

Table 1 Disease epidemiological and cost data

	Value	Reference
Chlamydia Prevalence	.08/6.7	[12, 14]
NAAT chlamydia screen
Sensitivity	0.98	[15]
Cost^a	$33.48	Medicaid Reimbursement Rate
Chlamydia Treatment w/Azithromycin
Success Rate	0.97	[31]
Cost ^a	$1.86	[16]
PID
Prevalence	0.27	[32]
Cost	$10,420	[8, 28]
Miscarriage
Prevalence	0.079	[33]
Cost	$1,000	[34]
Preterm Delivery
Prevalence	0.007	[35]
Cost ^a	$51,589	[36]
Vertical Transmission
Prevalence	0.46	[12]
Neonatal Conjunctivitis
Prevalence	0.41	[12]
Cost ^a	$83.23	[5]
Neonatal pneumonia
Prevalence	0.16	[12]
Cost ^a	$577.11	[5]
Infertility
Infertility associated with Chlamydia	.00845	[37]
Infertility associated with PID	.123	[37]
Prevalence	0.33	[38]
Cost ^a	$6060.82	[39, 40]

ISSN: 1471-2334